Structure-activity relationships of orotidine-5′-monophosphate decarboxylase inhibitors as anticancer agents

Journal of Medicinal Chemistry

Volumn 52, Issue 6, 2009, Pages 1648-1658

  Bello, Angelica M ^a   Konforte, Danijela ^b   Poduch, Ewa ^a   Furlonger, Caren ^b   Wei, Lianhu ^a   Liu, Yan ^d   Lewis, Melissa ^a   Pai, Emil F ^b,d   Paige, Christopher J ^b,c   Kotra, Lakshmi P ^a,d,e,f  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^f MaRS Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 6 AMINOURIDINE; 5 FLUORO 6 AMINOURIDINE 5' O MONOPHOSPHATE; 5 FLUORO 6 AZIDO URIDINE; 5 FLUORO 6 AZIDOURIDINE 5' O MONOPHOSPHATE; 5 FLUORO 6 CARBALDEHYDE URIDINE; 5 FLUORO 6 ETHYLURIDINE; 5 FLUORO 6 ETHYLURIDINE 5' O MONOPHOSPHATE; 5 FLUORO 6 IODOURIDINE; 5 FLUORO 6 IODOURIDINE 5' O MONOPHOSPHATE; 5' O (T BUTYLDIMETHYLSILYL) 2',3' O ISOPROPYLIDENE 5 FLUORO 6 AZIDO URIDINE; 5' O (T BUTYLDIMETHYLSILYL) 2',3' O ISOPROPYLIDENE 5 FLUORO 6 CARBALDEHYDEURIDINE; 5' O (T BUTYLDIMETHYLSILYL) 2',3' O ISOPROPYLIDENE 5 FLUORO 6 ETHYLURIDINE; 5' O (T BUTYLDIMETHYLSILYL) 2',3' O ISOPROPYLIDENE 5 FLUORO 6 IODOURIDINE; 5' O (T BUTYLDIMETHYLSILYL) 2',3' O ISOPROPYLIDENE 5 FLUOROURIDINE; FLUOROURIDINE; LYSINE; OROTIDINE 5' PHOSPHATE DECARBOXYLASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG DESIGN; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LIGAND BINDING; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; OROTIDINE-5'-PHOSPHATE DECARBOXYLASE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 64349090835     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801224t     Document Type: Article

References (43)

1. Galmarini, C. M.; Popowickz, F.; Joseph, B. Cytotoxic nucleoside analogs: different strategies to improve their clinical efficacy. Curr. Med. Chem. 2008, 15, 1072-1082.
2. Uga, H.; Kuramori, C.; Ohta, A.; Tsuboi, Y.; Tanaka, H.; Hatakeyama, M.; Yamaguchi, Y.; Takahashi, T.; Kizaki, M.; Handa, H. A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol. Pharmacol. 2006, 70, 1832-1839.
3. Warshel, A.; Florian, J. Computer simulations of enzyme catalysis: finding out what has been optimized by evolution. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 5950-5955.
4. Miller, B. G.; Wolfenden, R. Catalytic proficiency: The unusual case of OMP decarboxylase. Annu. Rev. Biochem. 2002, 71, 847-885.
5. Sievers, A.; Wolfenden, R. Equilibrium of formation of the 6-carbanion of UMP, a potential intermediate in the action of OMP decarboxylase. J. Am. Chem. Soc. 2002, 124, 13986-13987.
6. Snider, M. J.; Wolfenden, R. The rate of spontaneous decarboxylation of amino acids. J. Am. Chem. Soc. 2000, 122, 11507-11508.
7. Richard, P. The enzymatic synthesis of pyrimidines. Adv. Enzymol. Mol. Biol. 1959, 21, 263-294.
8. Meza-Avina, M. E.; Wei, L.; Buhendwa, M. G.; Poduch, E.; Bello, A. M.; Pai, E. F.; Kotra, L. P. Inhibition of orotidine 5′-monophosphate decarboxylase and its therapeutic potential. Mini-Rev. Med. Chem. 2008, 8, 239-247.
9. Christopherson, R. I.; Lyons, S. D.; Wilson, P. K. Inhibitors of de novo nucleotide biosynthesis as drugs. Acc. Chem. Res. 2002, 35, 961-971.
10. Scott, H. V.; Gero, A. M.; O'Sullivan, W. J. In vitro inhibition of Plasmodium falciparum by Pyrazofurin, an inhibitor of pyrimidine biosynthesis de novo. Mol. Biochem. Parasitol. 1986, 18, 3-15.
11. Levine, H. L.; Brody, R. S.; Westheimer, F. H. Inhibition of orotidine-5′-phosphate decarboxylase by 1-(5′-phospho-b-d- ribofuranosyl)bar-bituric acid, 6-azauridine-5′-phosphate, and uridine 5′-phosphate. Biochemistry 1980, 19, 4993-4999.
12. Gero, A. M.; O'Sullivan, W. J. Purines and pyrimidines in malarial parasites. Blood Cells 1990, 16, 467-484.
13. Seymour, K. K.; Lyons, S. D.; Phillips, L.; Rieckmann, K. H.; Christopherson, R. I. Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum. Biochemistry 1994, 33, 5268-5274.
14. Krungkrai, J.; Krungkrai, S. R.; Phakanont, K. Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem. Pharmacol. 1992, 43, 1295-1301.
15. Smiley, J. A.; Saleh, L. Active site probes for yeast OMP decarboxy-lase: Inhibition constants of UMP and thio-substituted UMP analogues and greatly reduced activity toward CMP-6-carboxylate. Bioorg. Chem. 1999, 27, 297-306.
16. Gabrielsen, B.; Kirsi, J. J.; Kwong, C. D.; Carter, D. A.; Krauth, C. A.; Hanna, L. K.; Huggins, J. W.; Monath, T. P.; Kefauver, D. F.; Blough, H. A.; Rankin, J. T.; Bartz, C. M.; Huffman, J. H.; Smee, D. F.; Sidwell, R. W.; Shannon, W. M.; Secrist, J. A. In vitro and in vivo antiviral (RNA) evaluation of orotidine ′-monophosphate decarboxy-lase inhibitors and analogs including 6-azauridine-5′-(ethyl methoxy-alaninyl)phosphate (a 5′-monophosphate prodrug). Antiviral Chem. Chemother. 1994, 5, 209-220.
17. Nord, L. D.; Willis, R. C.; Smee, D. F.; Riley, T. A.; Revankar, G. R.; Robins, R. K. Inhibition of orotidylate decarboxylase by 4(5H)-oxo-1- beta-d-ribofuranosylpyrazolo[3,4-d]pyrimidine-3-thiocarboxamide (APR-TC) in B lymphoblasts. Activation by adenosine kinase. Biochem. Pharmacol. 1988, 37, 4697-4705.
18. Smee, D. F.; McKernan, P. A.; Nord, L. D.; Willis, R. C.; Petrie, C. R.; Riley, T. M.; Revankar, G. R.; Robins, R. K.; Smith, R. A. Novel pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity. Anitmicrob. Agents.Chemother. 1987, 31, 1535-1541.
19. Jones, M. E. Pyrimidine nucleotide biosynthesis in animals: Genes, enzymes, and regulation of UMP biosynthesis. Annu. Rev. Biochem. 1980, 49, 253-279.
20. Chen, J. J.; Jones, M. E. Effect of 6-azauridine on de novo pyrimidine biosynthesis in cultured Ehrlich ascites cells. Orotate inhibition of dihydrorotase and dihydroorotase dehydrogenase. J. Biol. Chem. 1979, 254, 4908-4914.
21. Cadman, E. C.; Dix, D. E.; Handschumacher, R. E. Clinical, biological and biochemical effect of Pyrazofurin. Cancer Res. 1978, 38, 682-698.
22. Cihak, A.; Veseley, J.; Skoda, J. Azapyrimidine nucleosides: metabolism and inhibitory mechanism. Adv. Enzyme Regul. 1985, 24, 235-254.
23. Miller, B. G.; Hassell, A. M.; Wolfenden, R.; Milburn, M. V.; Short, S. A. Anatomy of a proficient enzyme: The structure of orotidine 5′-monophosphate decarboxylase in the presence and absence of a potential transition-state analog. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2011-2016.
24. Dix, D. E.; Lehman, C. P.; Jakubowski, A.; Moyer, J. D.; Handschu-macher, R. E. Pyrazofurin metabolism, enzyme inhibition, and resistance in L5178Y cells. Cancer Res. 1979, 39, 4485-4490.
25. Sant, M. E.; Lyons, S. D.; Kemp, A. J.; McClure, L. K.; Szabados, E.; Christopherson, R. I. Dual effects of Pyrazofurin and 3-deazauridine upon pyrimidine and purine biosynthesis in mouse L1210 leukemia. Cancer. Res. 1989, 49, 2645-2650.
26. Harris, P.; Poulsen, J. C. N.; Jensen, K. F.; Larsen, S. Substrate binding induces domain movements in orotidine 5′-monophosphate decar-boxylase. J. Mol. Biol. 2002, 318, 1019-1029.
27. Wu, N.; Mo, Y.; Gao, J.; Pai, E. F. Electrostatic stress in catalysis: structure and mechanism of the enzyme orotidine monophosphate decarboxylase. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2017-2022.
28. Appleby, T. C.; Kinsland, C.; Begley, T. P.; Ealick, S. E. The crystal structure and mechanism of orotidine 5′-monophosphate decarboxylase. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2005-2010.
29. Miller, B. G.; Hassell, A. M.; Wolfenden, R.; Milburn, M. V.; Short, S. A. Anatomy of a proficient enzyme: the structure of orotidine 5′-monophosphate decarboxylase in the presence and absence of a potential transition state analog. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2011-2016.
30. Lee, T. S.; Chong, L. T.; Chodera, J. D.; Kollman, P. A. An alternative explanation for the catalytic proficiency of orotidine 5′-phosphate decarboxylase. J. Am. Chem. Soc. 2001, 123, 12837-12848.
31. Miller, B. G.; Butterfoss, G. L.; Short, S. A.; Wolfenden, R. Role of enzyme-ribofuranosyl contacts in the ground state and transition state for orotidine 5′-phosphate decarboxylase: a role for substrate desta-bilization. Biochemistry 2001, 40, 6227-6232.
32. Warshel, A.; Strajbl, M.; Villa, J.; Florian, J. Remarkable rate enhancement of orotidine 5′-monophosphate decarboxylase is due to transition-state stabilization rather than to ground-state destabilization. Biochemistry 2000, 39, 14728-14738.
33. Fujihashi, M.; Bello, A. M.; Poduch, E.; Wei, L.; Annedi, S. C.; Pai, E. F.; Kotra, L. P. An unprecedented twist to ODCase catalytic activity. J. Am. Chem. Soc. 2005, 127, 15048-15050.
34. Poduch, E.; Bello, A. M.; Tang, S.; Fujihashi, M.; Pai, E. F.; Kotra, L. P. Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics. J. Med. Chem. 2006, 49, 4937-4945.
35. Bello, A. M.; Poduch, E.; Fujihashi, M.; Amani, M.; Li, Y.; Crandall, I.; Hui, R.; Lee, P. I.; Kain, K. C.; Pai, E. F.; Kotra, L. P. A potent, covalent inhibitor of ODCase with antimalarial activity. J. Med. Chem. 2007, 50, 915-921.
36. Bello, A. M.; Poduch, E.; Liu, Y.; Wei, L.; Crandall, I.; Wang, X.; Dyanand, C.; Kain, K. C.; Pai, E. F.; Kotra, L. P. Structure-Activity Relationships of C6-Uridine Derivatives Targeting Plasmodia Orotidine Monophosphate Decarboxylase. J. Med. Chem. 2008, 51, 439-448.
37. Damaraju, D.; Damaraju, V. L.; Brun, M.; Mowles, D.; Kuzma, M.; Berendt, R. C.; Sawyer, M. B.; Cass, C. E. Cytotoxic activities of nucleoside and nucleobase analog drugs in malignant mesothelioma: characterization of a novel nucleobase transport activity. Biochem. Pharmacol. 2008, 15, 1901-1911.
38. Tanaka, H.; Matsuda, A.; Iijima, S.; Hayakawa, H.; Miyasaka, T. Synthesis and biological activities of 5-substituted 6-phenylthio and 6-iodouridines, a new class of antileukemic nucleosides. Chem. Pharm. Bull. 1983, 31, 2164-2167.
39. Poduch, E.; Wei, L.; Pai, E. F.; Kotra, L. P. Structural diversity and plasticity associated with nucleotides targeting orotidine monophos-phate decarboxylase. J. Med. Chem. 2008, 51, 432-438.
40. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
41. Vagin, A.; Teplyakov, A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30, 1022-1025.
42. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likehood method. Acta Crystallogr, Sect. D: Biol. Crystallogr. 1997, 53, 240-255.
43. Emsley, P.; Cowtan, K. Model building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, D60, 2126-2132. JM801224T